Neumora Therapeutics posts corporate presentation on neuroscience drug development strategy
NMRA•NMRA-215 obesity program
NMRA-215, an NLRP3 inhibitor, has an IND submission targeted for 4Q 2026, with a Phase 1 start planned by year-end 2026 for obesity.
Preclinical DIO studies showed up to 19% weight loss on NMRA-215 monotherapy and up to 26% when combined with semaglutide.
NMRA-511 and NMRA-898 clinical updates
NMRA-511, a V1aR antagonist, showed a Phase 1b result in Alzheimer’s agitation with Cohen’s d 0.34 at Week 8 in the NPI-AA ≥4 population.
NMRA-898, an M4 modulator, has Phase 1 data expected in 2H 2026 for schizophrenia. A Phase 2 for NMRA-511 is also planned by year-end 2026.
Corporate presentation outlines neuroscience pipeline
Neumora outlined a pipeline spanning cardiometabolic, neurodegenerative, and neuropsychiatric programs, with multiple readouts expected in 2026.
